Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 466

1.

Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation.

Pokorney SD, Holmes DN, Shrader P, Thomas L, Fonarow GC, Mahaffey KW, Gersh BJ, Kowey PR, Naccarelli GV, Freeman JV, Singer DE, Washam JB, Peterson ED, Piccini JP, Reiffel JA.

Am Heart J. 2019 Oct 23;220:145-154. doi: 10.1016/j.ahj.2019.09.017. [Epub ahead of print]

PMID:
31812756
2.

Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial.

Ward R, Huang Z, Rockhold FW, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Katona BG, Mahaffey KW, Norgren L, Vemulapalli S, Povsic TJ, Mehta R, Hiatt WR, Patel MR, Jones WS.

Am Heart J. 2019 Nov 18;220:51-58. doi: 10.1016/j.ahj.2019.11.007. [Epub ahead of print]

PMID:
31783279
3.

A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation.

Olivier CB, Sundaram V, Chertow GM, Shashidhar S, McDonnell LK, Ding VY, Desai M, Mahaffey KW, Mell M.

J Vasc Access. 2019 Nov 27:1129729819887269. doi: 10.1177/1129729819887269. [Epub ahead of print]

PMID:
31774037
4.

Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.

Sharma A, Wu J, Ezekowitz JA, Felker GM, Udell JA, Heidenreich PA, Fonarow GC, Mahaffey KW, Hernandez AF, DeVore AD.

ESC Heart Fail. 2019 Nov 20. doi: 10.1002/ehf2.12528. [Epub ahead of print]

5.

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program.

Ohkuma T, Van Gaal L, Shaw W, Mahaffey KW, de Zeeuw D, Matthews DR, Perkovic V, Neal B.

Diabetes Obes Metab. 2019 Nov 14. doi: 10.1111/dom.13920. [Epub ahead of print]

PMID:
31729107
6.

Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation.

Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, Balasubramanian V, Russo AM, Rajmane A, Cheung L, Hung G, Lee J, Kowey P, Talati N, Nag D, Gummidipundi SE, Beatty A, Hills MT, Desai S, Granger CB, Desai M, Turakhia MP; Apple Heart Study Investigators.

N Engl J Med. 2019 Nov 14;381(20):1909-1917. doi: 10.1056/NEJMoa1901183.

PMID:
31722151
7.

Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation.

Loring Z, Shrader P, Allen LA, Blanco R, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV, Gersh BJ, Mahaffey KW, Naccarelli GV, Pieper K, Reiffel JA, Singer DE, Steinberg BA, Thomas LE, Peterson ED, Piccini JP.

Am Heart J. 2019 Nov 8;219:21-30. doi: 10.1016/j.ahj.2019.10.008. [Epub ahead of print]

PMID:
31710841
8.

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial.

Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW.

Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044359. [Epub ahead of print]

PMID:
31707795
9.

Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.

Li J, Woodward M, Perkovic V, Figtree GA, Heerspink HJL, Mahaffey KW, de Zeeuw D, Vercruysse F, Shaw W, Matthews DR, Neal B.

JACC Heart Fail. 2019 Oct 23. pii: S2213-1779(19)30677-8. doi: 10.1016/j.jchf.2019.08.004. [Epub ahead of print]

10.

Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial.

Kansal A, Huang Z, Rockhold FW, Baumgartner I, Berger JS, Blomster JI, Fowkes FG, Katona B, Mahaffey KW, Norgren L, Hiatt WR, Patel MR, Jones WS.

Circ Cardiovasc Interv. 2019 Oct;12(10):e008069. doi: 10.1161/CIRCINTERVENTIONS.119.008069. Epub 2019 Oct 4.

PMID:
31581789
11.

Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.

Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Li Q, Jardine M, Oh R, Heerspink HL, Perkovic V.

J Am Soc Nephrol. 2019 Nov;30(11):2229-2242. doi: 10.1681/ASN.2019010064. Epub 2019 Sep 17.

12.

Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply.

Jardine MJ, Mahaffey KW, Perkovic V.

N Engl J Med. 2019 Sep 12;381(11):1089-1090. doi: 10.1056/NEJMc1909687. No abstract available.

PMID:
31509685
13.

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.

Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C, Bompoint S, Levin A, Jardine MJ.

Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-854. doi: 10.1016/S2213-8587(19)30256-6. Epub 2019 Sep 5. Erratum in: Lancet Diabetes Endocrinol. 2019 Dec;7(12):e23.

PMID:
31495651
14.

Cardiovascular Risk Factors and Secondary Events Among Acute and Chronic Stable Myocardial Infarction Patients: Findings from a Managed Care Database.

Bash LD, White K, Patel MD, Liu J, Mavros P, Mahaffey KW.

Cardiol Ther. 2019 Dec;8(2):329-343. doi: 10.1007/s40119-019-00147-5. Epub 2019 Aug 20.

15.

Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention.

Olivier CB, Fan J, Askari M, Mahaffey KW, Heidenreich PA, Perino AC, Leef GC, Ho PM, Harrington RA, Turakhia MP.

Circ Cardiovasc Interv. 2019 Aug;12(8):e007604. doi: 10.1161/CIRCINTERVENTIONS.118.007604. Epub 2019 Aug 16.

PMID:
31416357
16.

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.

Zhou Z, Jardine M, Perkovic V, Matthews DR, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Oh R, Simpson R, Watts NB, Neal B.

Diabetologia. 2019 Oct;62(10):1854-1867. doi: 10.1007/s00125-019-4955-5. Epub 2019 Aug 10.

17.

Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF.

Ungar L, Rodriguez F, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Singer DE, Patel MR, Piccini JP, Mahaffey KW.

Cardiol Ther. 2019 Dec;8(2):283-295. doi: 10.1007/s40119-019-00146-6. Epub 2019 Aug 2.

18.

A Cluster Analysis of the Japanese Multicenter Outpatient Registry of Patients With Atrial Fibrillation.

Inohara T, Piccini JP, Mahaffey KW, Kimura T, Katsumata Y, Tanimoto K, Inagawa K, Ikemura N, Ueda I, Fukuda K, Takatsuki S, Kohsaka S.

Am J Cardiol. 2019 Sep 15;124(6):871-878. doi: 10.1016/j.amjcard.2019.05.071. Epub 2019 Jun 25.

PMID:
31350002
19.

Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial.

Hopley CW, Kavanagh S, Patel MR, Ostrom C, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Jones WS, Katona BG, Mahaffey KW, Norgren L, Rockhold FW, Hiatt WR.

Vasc Med. 2019 Oct;24(5):422-430. doi: 10.1177/1358863X19864172. Epub 2019 Jul 24.

PMID:
31339474
20.

Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention.

Olivier CB, Bhatt DL, Leonardi S, Stone GW, Gibson CM, Steg PG, Hamm CW, Wilson MD, Mangum S, Price MJ, Prats J, White HD, Lopes RD, Harrington RA, Mahaffey KW; CHAMPION PHOENIX Investigators * .

Circ Cardiovasc Interv. 2019 Jul;12(7):e007342. doi: 10.1161/CIRCINTERVENTIONS.118.007342. Epub 2019 Jul 12.

PMID:
31296081
21.

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.

Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V.

Circulation. 2019 Aug 27;140(9):739-750. doi: 10.1161/CIRCULATIONAHA.119.042007. Epub 2019 Jul 11.

22.

Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.

Pokorney SD, Holmes DN, Thomas L, Fonarow GC, Kowey PR, Reiffel JA, Singer DE, Freeman JV, Gersh BJ, Mahaffey KW, Hylek EM, Naccarelli GV, Ezekowitz MD, Piccini JP, Peterson ED; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators.

JAMA Cardiol. 2019 Jul 3. doi: 10.1001/jamacardio.2019.1960. [Epub ahead of print]

23.

The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX.

Yong CM, Sundaram V, Abnousi F, Olivier CB, Yang J, Stone GW, Steg PG, Michael Gibson C, Hamm CW, Price MJ, Deliargyris EN, Prats J, White HD, Harrington RA, Bhatt DL, Mahaffey KW; CHAMPION PHOENIX Investigators.

Clin Cardiol. 2019 Jun 29. doi: 10.1002/clc.23221. [Epub ahead of print]

24.

Acute Limb Ischemia in Peripheral Artery Disease.

Hess CN, Huang Z, Patel MR, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Held P, Jones WS, Katona B, Mahaffey KW, Norgren L, Rockhold FW, Hiatt WR.

Circulation. 2019 Aug 13;140(7):556-565. doi: 10.1161/CIRCULATIONAHA.119.039773. Epub 2019 Jun 26.

PMID:
31238713
25.

Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II.

Inohara T, Shrader P, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Go AS, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP; ORBIT AF Patients and Investigators.

Am Heart J. 2019 Jul;213:81-90. doi: 10.1016/j.ahj.2019.04.007. Epub 2019 Apr 24.

PMID:
31129441
26.

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.

White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lopes RD, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Sritara P, Tricoci P, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators.

Eur Heart J. 2019 Sep 1;40(33):2801-2809. doi: 10.1093/eurheartj/ehz299.

27.

Effect of Alirocumab on Mortality After Acute Coronary Syndromes.

Steg PG, Szarek M, Bhatt DL, Bittner VA, Brégeault MF, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Ostadal P, Parkhomenko A, Pordy R, Roe MT, Tricoci P, Vogel R, White HD, Zeiher AM, Schwartz GG.

Circulation. 2019 Jul 9;140(2):103-112. doi: 10.1161/CIRCULATIONAHA.118.038840. Epub 2019 May 23. Erratum in: Circulation. 2019 Jul 23;140(4):e171.

28.

Stroke in Patients With Peripheral Artery Disease.

Kolls BJ, Sapp S, Rockhold FW, Jordan JD, Dombrowski KE, Fowkes FGR, Mahaffey KW, Berger JS, Katona BG, Blomster JI, Norgren L, Abramson BL, Leiva-Pons JL, Prieto JC, Sokurenko G, Hiatt WR, Jones WS, Patel MR.

Stroke. 2019 Jun;50(6):1356-1363. doi: 10.1161/STROKEAHA.118.023534. Epub 2019 May 16.

PMID:
31092165
29.

Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF Registry.

Perino AC, Shrader P, Turakhia MP, Ansell JE, Gersh BJ, Fonarow GC, Go AS, Kaiser DW, Hylek EM, Kowey PR, Singer DE, Thomas L, Steinberg BA, Peterson ED, Piccini JP, Mahaffey KW.

J Am Heart Assoc. 2019 May 7;8(9):e011205. doi: 10.1161/JAHA.118.011205.

30.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

31.

Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation.

Madhavan M, Holmes DN, Piccini JP, Ansell JE, Fonarow GC, Hylek EM, Kowey PR, Mahaffey KW, Thomas L, Peterson ED, Chan P, Allen LA, Gersh BJ; ORBIT AF Investigators.

Am Heart J. 2019 May;211:77-89. doi: 10.1016/j.ahj.2019.01.005. Epub 2019 Jan 30.

PMID:
30901602
32.

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.

Figtree GA, Rådholm K, Barrett TD, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Neal B.

Circulation. 2019 May 28;139(22):2591-2593. doi: 10.1161/CIRCULATIONAHA.119.040057. Epub 2019 Mar 17. No abstract available.

33.

Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment.

Abtan J, Ducrocq G, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris EN, White HD, Harrington RA, Bhatt DL.

Circ Cardiovasc Interv. 2019 Mar;12(3):e007445. doi: 10.1161/CIRCINTERVENTIONS.118.007445.

PMID:
30871355
34.

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.

Matthews DR, Li Q, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Hiatt WR, Nehler M, Fabbrini E, Kavalam M, Lee M, Neal B.

Diabetologia. 2019 Jun;62(6):926-938. doi: 10.1007/s00125-019-4839-8. Epub 2019 Mar 12.

35.

Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry).

Vemulapalli S, Inohara T, Kim S, Thomas L, Piccini JP, Patel MR, Chang P, Fonarow GC, Ezekowitz MD, Hylek E, Go AS, Kowey PR, Mahaffey KW, Gersh BJ, Peterson ED.

Am J Cardiol. 2019 May 15;123(10):1628-1636. doi: 10.1016/j.amjcard.2019.02.010. Epub 2019 Feb 23.

PMID:
30846214
36.

Characteristics of Digital Health Studies Registered in ClinicalTrials.gov.

Chen CE, Harrington RA, Desai SA, Mahaffey KW, Turakhia MP.

JAMA Intern Med. 2019 Jun 1;179(6):838-840. doi: 10.1001/jamainternmed.2018.7235. No abstract available.

PMID:
30801617
37.

Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration.

Leef GC, Perino AC, Askari M, Fan J, Ho PM, Olivier CB, Longo L, Mahaffey KW, Turakhia MP.

J Pharm Pract. 2019 Feb 21:897190019828270. doi: 10.1177/0897190019828270. [Epub ahead of print]

PMID:
30791808
38.

Canagliflozin review - safety and efficacy profile in patients with T2DM.

Jakher H, Chang TI, Tan M, Mahaffey KW.

Diabetes Metab Syndr Obes. 2019 Feb 1;12:209-215. doi: 10.2147/DMSO.S184437. eCollection 2019. Review.

39.

Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial.

Gutierrez JA, Mulder H, Jones WS, Rockhold FW, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Held P, Katona BG, Mahaffey KW, Norgren L, Hiatt WR, Patel MR.

JAMA Netw Open. 2018 Nov 2;1(7):e185239. doi: 10.1001/jamanetworkopen.2018.5239.

40.

Canagliflozin and Stroke in Type 2 Diabetes Mellitus.

Zhou Z, Lindley RI, Rådholm K, Jenkins B, Watson J, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Shaw W, Oh R, Desai M, Matthews DR, Neal B.

Stroke. 2019 Feb;50(2):396-404. doi: 10.1161/STROKEAHA.118.023009.

41.

Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials.

Fanaroff AC, Clare R, Pieper KS, Mahaffey KW, Melloni C, Green JB, Alexander JH, Jones WS, Harrison RW, Mehta RH, Povsic TJ, Moreira HG, Al-Khatib SM, Roe MT, Kong DF, Mathews R, Tricoci P, Holman RR, Wallentin L, Held C, Califf RM, Alexander KP, Lopes RD.

Circulation. 2019 Feb 12;139(7):863-873. doi: 10.1161/CIRCULATIONAHA.118.037202.

PMID:
30586739
42.

Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial.

Low Wang CC, Blomster JI, Heizer G, Berger JS, Baumgartner I, Fowkes FGR, Held P, Katona BG, Norgren L, Jones WS, Lopes RD, Olin JW, Rockhold FW, Mahaffey KW, Patel MR, Hiatt WR; EUCLID Trial Executive Committee and Investigators.

J Am Coll Cardiol. 2018 Dec 25;72(25):3274-3284. doi: 10.1016/j.jacc.2018.09.078. Erratum in: J Am Coll Cardiol. 2019 Jul 16;74(2):264-269.

PMID:
30573030
43.

Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.

Held C, White HD, Stewart RAH, Davies R, Sampson S, Chiswell K, Silverstein A, Lopes RD, Heldestad U, Budaj A, Mahaffey KW, Wallentin L; STABILITY Investigators.

Am Heart J. 2019 Feb;208:65-73. doi: 10.1016/j.ahj.2018.10.010. Epub 2018 Nov 7.

44.

Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial.

Abtan J, Ducrocq G, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm C, Price MJ, Prats J, Elkin S, Deliargyris EN, White HD, Menozzi A, Harrington RA, Bhatt DL; MPH on Behalf of the CHAMPION PHOENIX Investigators.

Int J Cardiol. 2019 Mar 1;278:217-222. doi: 10.1016/j.ijcard.2018.11.114. Epub 2018 Nov 23.

45.

Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.

Olivier CB, Mulder H, Hiatt WR, Jones WS, Fowkes FGR, Rockhold FW, Berger JS, Baumgartner I, Held P, Katona BG, Norgren L, Blomster J, Patel MR, Mahaffey KW.

JAMA Cardiol. 2019 Jan 1;4(1):7-15. doi: 10.1001/jamacardio.2018.4171.

46.

Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial.

Ungar L, Clare RM, Rodriguez F, Kolls BJ, Armstrong PW, Aylward P, Held C, Moliterno DJ, Strony J, Van de Werf F, Wallentin L, White HD, Tricoci P, Harrington RA, Mahaffey KW, Melloni C.

J Am Heart Assoc. 2018 Dec 18;7(24):e009609. doi: 10.1161/JAHA.118.009609.

47.

Reviewing the role of healthy volunteer studies in drug development.

Karakunnel JJ, Bui N, Palaniappan L, Schmidt KT, Mahaffey KW, Morrison B, Figg WD, Kummar S.

J Transl Med. 2018 Dec 4;16(1):336. doi: 10.1186/s12967-018-1710-5. Review.

48.

Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II.

Essien UR, Holmes DN, Jackson LR 2nd, Fonarow GC, Mahaffey KW, Reiffel JA, Steinberg BA, Allen LA, Chan PS, Freeman JV, Blanco RG, Pieper KS, Piccini JP, Peterson ED, Singer DE.

JAMA Cardiol. 2018 Dec 1;3(12):1174-1182. doi: 10.1001/jamacardio.2018.3945.

49.

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.

Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Kimura T, Kiss RG, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Tricoci P, Xavier D, Zeiher AM, Steg PG; ODYSSEY OUTCOMES Committees and Investigators.

J Am Coll Cardiol. 2019 Feb 5;73(4):387-396. doi: 10.1016/j.jacc.2018.10.039. Epub 2018 Nov 11.

50.

Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.

Lindholm D, James SK, Gabrysch K, Storey RF, Himmelmann A, Cannon CP, Mahaffey KW, Steg PG, Held C, Siegbahn A, Wallentin L.

JAMA Cardiol. 2018 Dec 1;3(12):1160-1166. doi: 10.1001/jamacardio.2018.3811.

Supplemental Content

Loading ...
Support Center